Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2025-10-29 Interim / Quarterly Rep…
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2025 年第三季度报告" which translates to "2025 Third Quarter Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow data, and extensive financial metrics for the quarter ending September 30, 2025. The document explicitly states it is a quarterly report and includes comprehensive financial data and analysis for the period. It is unaudited but contains substantive financial information typical of an interim or quarterly report. There is no indication that this is an announcement of a report or a certification letter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-10-29 Chinese
第六届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 23rd meeting of the 6th Board of Directors of Beijing Northland Biotechnology Co., Ltd. It includes details about the meeting date, attendance, and the approval of the 2025 third quarter report. However, the actual 2025 third quarter report is not included in this document; instead, it references that the report was disclosed separately on the Beijing Stock Exchange information disclosure platform. The document is short (1037 characters) and serves as a meeting resolution announcement rather than the report itself. Therefore, it is best classified as a Board/Management Information (MANG) filing, which covers announcements of board decisions and management matters.
2025-10-29 Chinese
关于筹划发行H股股票并在香港联合交易所上市的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (784 characters) regarding the company's plan to issue H shares and list on the Hong Kong Stock Exchange. It discusses the intention, regulatory requirements, and the uncertainty of the process. There is no detailed financial data, no actual issuance or listing completed, and no comprehensive report attached. The document serves as a preliminary notice or update about capital raising plans and listing intentions, which fits the category of Capital/Financing Update (CAP). It is not a full report, nor a regulatory filing or announcement of a report publication. Therefore, the best classification is CAP.
2025-10-09 Chinese
关于使用部分闲置自有资金委托理财的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Northland Biotechnology Co., Ltd. regarding the progress of using part of its idle own funds for entrusted wealth management. It details the authorization, amounts, counterparties, product types, risk controls, and investment returns related to the entrusted wealth management products. The document is a disclosure about financing activities involving the company's own funds, specifically about investment in financial products to increase returns. It is not a financial report, earnings release, or regulatory certification. It is a specific update on capital usage and financing activities. Therefore, the document fits best under the category 'Capital/Financing Update' (CAP). The document length is 4444 characters, which is sufficient for a detailed announcement rather than a brief notice or report publication announcement.
2025-10-09 Chinese
2025年第二次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 second extraordinary shareholders' meeting of Beijing Northland Biotechnology Co., Ltd. It includes information about the meeting's convening, attendance, voting results on various proposals, legal opinions, and personnel changes effective from the meeting. The content focuses on the official voting results and decisions made by shareholders during the meeting, including amendments to company bylaws and management systems. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is not a presentation or a proxy solicitation but an official declaration of voting results from a shareholders' meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4222 characters, which is sufficient to contain detailed voting results rather than just an announcement of a report publication (RPA).
2025-09-17 Chinese
北京海润天睿律师事务所关于北京诺思兰德生物技术股份有限公司2025年第二次临时股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, and voting procedures of the company's 2025 second extraordinary general meeting of shareholders. It details the meeting's notice, attendance, voting results on various proposals, and confirms the legality and validity of the meeting and its resolutions. This is not a full annual or interim report, nor an earnings release or management discussion. It is not a proxy solicitation or a director dealing report. The document is focused on the official voting results and legal validation of the shareholder meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 4829 characters, which is sufficient to contain detailed voting results and legal opinions, not just an announcement of a report publication. Hence, the classification is DVA with high confidence.
2025-09-17 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.